Hepatitis C: Difference between revisions

From Guide to YKHC Medical Practices

No edit summary
No edit summary
Line 3: Line 3:
If a patient is to be started on glecaprevir/pibrentasvir, the [http://dhss.alaska.gov/dhcs/Documents/pharmacy/forms/AK_Hep_C_DAA_Fax_Form_20171001.pdf medication prior authorization form] needs to be filled out by BOTH patient and provider prior to the medication being dispensed. It is ideal to have this form completed during the visit and given to your clinic pharmacist when sending the Rx to the pharmacy.  
If a patient is to be started on glecaprevir/pibrentasvir, the [http://dhss.alaska.gov/dhcs/Documents/pharmacy/forms/AK_Hep_C_DAA_Fax_Form_20171001.pdf medication prior authorization form] needs to be filled out by BOTH patient and provider prior to the medication being dispensed. It is ideal to have this form completed during the visit and given to your clinic pharmacist when sending the Rx to the pharmacy.  


[https://www.anthc.org/what-we-do/clinical-and-research-services/hep/hep-c-treatment-information/|ANTHC Hepatitis C Treatment]
[https://www.anthc.org/what-we-do/clinical-and-research-services/hep/hep-c-treatment-information/ | ANTHC Hepatitis C Treatment]


===Resources/References===
===Resources/References===

Revision as of 13:54, 2 August 2023

Anyone with untreated Hepatitis C can be given glecaprevir/pibrentasvir (Mavyret™) for 8 weeks. Please call the ANMC Hepatology team with any questions and see the Resources below for a link to the Prior Authorization Form.

If a patient is to be started on glecaprevir/pibrentasvir, the medication prior authorization form needs to be filled out by BOTH patient and provider prior to the medication being dispensed. It is ideal to have this form completed during the visit and given to your clinic pharmacist when sending the Rx to the pharmacy.

| ANTHC Hepatitis C Treatment

Resources/References


Common/Unique Medical Diagnoses